Clinical Trial Update: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) [Phase 3]

View source ↗

Summary

An update on a Phase 3 rollover trial of Osimertinib (Tagrisso) for patients who completed a prior oncology study. The study is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING